Metabolomic biomarker differences of sarcopenia in older patients with sepsis
-
By
-
Yiyang Liu
-
Tianren He
-
Siyu Chen
-
Ziyi Li
-
Xue Mei
-
Xinhua He
-
Na Shang
-
April 30, 2026
-
Clinical Scorecard: Metabolomic Differences Associated with Sarcopenia in Elderly Patients Experiencing Sepsis
At a Glance
| Category | Detail |
|---|
| Condition | Sarcopenia in elderly patients with sepsis |
| Key Mechanisms | Metabolic profile changes characterized by downregulation of muscle synthesis pathways and upregulation of catabolic pathways. |
| Target Population | Older patients (≥65 years) with sepsis |
| Care Setting | Emergency Department |
Key Highlights
- 84 older patients with sepsis studied, divided into sarcopenia (35) and non-sarcopenia (49) groups.
- Identified 203 differential metabolites; 71 upregulated and 132 downregulated.
- Core pathways affected include branched-chain amino acid degradation and steroid hormone synthesis.
- Metabolic profile indicates an 'inhibitory' feature in sarcopenic patients.
- Findings suggest potential targets for early diagnostic biomarkers and intervention strategies.
Guideline-Based Recommendations
Diagnosis
- Diagnosis based on the 2019 Asian Sarcopenia Guidelines.
Management
- Focus on metabolic disorder characteristics for targeted interventions.
Monitoring & Follow-up
- Regular assessment of muscle mass and strength in elderly sepsis patients.
Risks
- Increased risk of poor prognosis and adverse outcomes in sarcopenic patients.
Patient & Prescribing Data
Elderly patients (≥65 years) with sepsis.
Understanding metabolic profiles may guide therapeutic strategies.
Clinical Best Practices
- Utilize metabolomic analysis for assessing sarcopenia in sepsis.
- Incorporate nutritional support focusing on muscle synthesis pathways.
Related Resources & Content
